
Biosimilars Insights
Evaluation of the risks, opportunities, and strategies underlying biosimilars development and defense.
Already a Subscriber?
Evaluation of the risks, opportunities, and strategies underlying biosimilars development and defense.
Obtain a full view of market and competitive positioning with reliable and up-to-date product analysis and worldwide net sales roll ups by molecule, therapy area, and company.
Utilize a multi-client subscription service to enable drug label and label claim comparisons across geographies and therapeutic areas.
The complexity of the medtech purchasing ecosystem has rendered a traditional approach ineffective. Here's how to get up to speed...
Commercial availability of two anti-CD19 CAR T-cell therapies (Kite/Gilead’s Yescarta and Novartis’ Kymriah) has...
In Massachusetts, Drug Coupons on the Brink Drug manufacturers are concerned that, barring legislative action, drug coupons in...
In DRG Blog, MedTech, Market Access / Nov, 2019
As advancements in technology-assisted treatments evolve, digital therapeutics are emerging as a vehicle for mental health and...
In DRG Blog, MedTech, Market Access / Nov, 2019
A Novartis subsidiary’s surprising exit last month from a closely-watched digital therapeutics partnership has prompted some...
In DRG Blog, MedTech, Market Access / Nov, 2019
Oct 01, 2019
Oct 01, 2019